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a b s t r a c t
The Epstein–Barr virus (EBV) predominantly establishes a latent infection in B lymphocytes, and
occasionally switches from the latent state to the lytic cycle. In this report, we identiﬁed and examined
the role of a lytic gene, BRRF2. We ﬁrst prepared an antibody against BRRF2 and identiﬁed the gene
product as a viral lytic protein expressed in B95-8 cells with late kinetics. Immunoﬂuorescence revealed
that BRRF2 localized in the cytoplasm of cells during the lytic phase. We also found that BRRF2 protein
was phosphorylated in lytic cells, but the only viral protein kinase, BGLF4, was not involved in the
phosphorylation. Knockout EBV and a repaired strain were then prepared, and we found that BRRF2
disruption did not affect viral gene expression and DNA replication, but decreased virus production.
These results demonstrated that BRRF2 is involved in production of infectious progeny, although it is not
essential for lytic replication.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The Epstein–Barr virus (EBV) is a human gamma-herpesvirus
present in most of the population worldwide. Its genome is approxi-
mately 170 kb in length and encodes more than 80 genes, indicating a
large virus with a complicated lifecycle. EBV is transmitted via saliva,
mostly during infancy or childhood, from close members of the family.
Upon infection, it establishes a latent infection predominantly in B
cells and remains in the host for the lifetime of the individual. Primary
infection during infancy is generally asymptomatic, but primary
infection during adolescence or adulthood can cause infectious
mononucleosis. EBV is also associated with several human malignan-
cies, including Burkitt lymphoma, Hodgkin lymphoma, nasopharyn-
geal carcinoma (NPC), and gastric cancer (Murata et al., 2014; Young
and Rickinson, 2004).
EBV can establish two types of infection in cells: latent and lytic
(Murata et al., 2014; Murata and Tsurumi,2014). In the latent state,
EBV genomic DNA exists in the nucleus as an episome, chroma-
tinized with histones, and expresses only a limited number of viral
latency genes (Lieberman, 2013). In the viral lytic cycle, all EBV
lytic genes are expressed, potent viral DNA genome replication
occurs, and progeny viral particles are produced (Hammerschmidt
and Sugden, 2013; Tsurumi et al., 2005). Switching from latent to
lytic states is called reactivation.
Physiological stimuli that trigger viral reactivation in vivo remain
unclear, but in cell culture reactivation can be triggered by either
chemical or biological agents, including 12-O-tetradecanoylphorbol-
13-acetate (TPA), histone deacetylase (HDAC) inhibitors, calcium
ionophores, anti-immunoglobulin (anti-Ig), and/or transforming
growth factor-beta (TGF-beta) (Murata and Tsurumi,2013, 2014).
Otherwise, reactivation can be fully induced by exogenous expression
of one of the viral immediate-early (IE) genes, BZLF1 (Zta, Z, ZEBRA,
EB1). As a b-zip transcription factor, BZLF1 can efﬁciently induce
expression of early (E) genes, such as DNA polymerase catalytic
subunit (BALF5), DNA polymerase processivity factor (BMRF1), and
single-stranded DNA-binding protein (BALF2). Using these E class
enzymes and proteins, EBV potently ampliﬁes its genome using a
rolling circle mechanism. Replication of the EBV genome occurs at
discrete sites in the nucleus known as replication compartments (Chiu
et al., 2013; Daikoku et al., 2005). Replication is followed by efﬁcient
production of late (L) genes, which encode viral structural proteins,
such as major capsid protein (MCP) and glycoproteins (Sugimoto et al.,
2013). Assembled icosahedral capsid structures incorporate viral
genomic DNA, while the nucleocapsid buds into the nuclear mem-
brane, acquire tegument proteins, and a glycoprotein envelope to
ultimately form progeny viral particles (Amon and Farrell, 2005;
Tsurumi et al., 2005).
EBV genes produced during a latent infection have been
studied extensively, but those expressed during the lytic cycle
have not been well-characterized. BRRF2 is located between
BRRF1 (also termed Na) and BKRF1 (EBNA1), and is conserved
only in gamma-herpesviruses (ORF48 of Kaposi's sarcoma-
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associated herpesvirus (KSHV) and in murine gamma-herpesvirus
68 (MHV-68)). Although the physiological roles of EBV BRRF2 have
never been reported, Johannsen et al. (2004) detected BRRF2 in
the EBV particles, most likely in the tegument. Likewise, Bortz
et al. (2003) showed that ORF48 of MHV-68 was associated with
virions. Transposon mutagenesis screening by the same group
indicated that ORF48 of MHV-68 is essential for lytic replication
(Song et al., 2005), but no other information is available at
this time.
To deﬁne the role of the BRRF2 gene, we prepared BRRF2-
knockout EBV for comparison with the wild-type virus. The
mutant showed no signiﬁcant reduction in viral protein expression
or DNA synthesis, but the viral titer of the mutant was decreased
in the medium, indicating that the BRRF2 gene is involved in
progeny virus production.
Results
Identiﬁcation of the BRRF2 protein
To detect BRRF2 protein, we ﬁrst prepared rabbit antiserum
against the BRRF2 polypeptide, followed by afﬁnity-puriﬁcation.
This antibody could speciﬁcally detect a 70-kDa BRRF2 protein
produced in vitro (Fig. 1A) and in EBV-positive B95-8 and HEK293
cells undergoing lytic replication (Fig. 1B).
To examine whether BRRF2 was expressed with E or L kinetics,
PAA was further examined, as shown in Fig. 1C (T/A/BþPAA).
While E proteins (BALF2 and BMRF1) were expressed even when
viral lytic DNA synthesis was inhibited by PAA, production of
BRRF2 protein was severely restricted by PAA, similar to the L
protein BALF4 (gB) (Fig. 1C). This suggested that BRRF2 is an EBV
lytic cycle gene expressed with late kinetics.
Next, intracellular localization of the BRRF2 protein was ana-
lyzed using immunoﬂuorescence in HEK293 EBV-BAC (Fig. 1D) and
B95-8 (Fig. 1E). The levels of BMRF1 and BRRF2 proteins, both of
which are expressed during the lytic replication cycle, were
minimal without lytic induction in HEK293 (Fig. 1D, vector).
Ectopic expression of the IE gene, BZLF1, induced lytic cycle
progression and resulted in the induction of BMRF1 and BRRF2
proteins (Fig. 1D, BZLF1). While BMRF1 was present predomi-
nantly in the nucleus (Kawashima et al., 2013; Nakayama et al.,
2010), BRRF2 was localized in the cytoplasm (Fig. 1D). When we
attempted to stain B95-8 cells with the anti-BRRF2 antibody,
background staining levels were non-negligible (not shown) for
reasons unknown. Therefore, we tagged BRRF2 protein in B95-8
cells. BMRF1 protein clearly formed replication compartments in
the nuclei when BZLF1 vector was transfected to induce lytic
replication (Fig. 1E, red). Unlike BMRF1, Flag-tagged BRRF2 mostly
localized in the cytoplasm with or without lytic induction by
BZLF1 (Fig. 1E, green). Since BRRF2 protein is a component of the
virion (Johannsen et al., 2004), EBV likely incorporates BRRF2 as
tegument material in the cytoplasm upon secondary envelopment
(Johnson and Baines, 2011).
Construction of an insertion mutant of BRRF2
To further analyze the biological functions of the EBV BRRF2
gene, we constructed a BRRF2-deﬁcient recombinant virus,
dBRRF2, as shown in Fig. 2A. In the 1614 nucleotides (from start
ATG to stop codon) of the BRRF2 open reading frame (ORF), the
marker cassette, which contains the neomycin resistance gene and
the streptomycin sensitivity gene (Neo/St), was inserted between
nt 660 and 661 for gene disruption. The cassette was then replaced
with a wild-type BRRF2 sequence to prepare the revertant virus,
dBRRF2/R.
These recombinant EBV genomes were analyzed based on
BamHI and EcoRI digestion followed by agarose gel electrophoresis
(Fig. 2B, C). The BamHI-R fragment was present in wild-type and
revertant (dBRRF2/R) viruses (white arrowhead), but the corre-
sponding bands of dBRRF2 virus migrated slowly in the gel. The
EcoRI-digestion pattern of the dBRRF2 virus was almost identical
to that of the wild-type and revertant because the cassette was
inserted into the second largest fragment and the shifting was not
distinguishable on the gel. Recombinant EBV DNAs were intro-
duced into HEK293 cells, and hygromycin-resistant cell colonies
were cloned for further analysis.
Viral protein expression, DNA replication, and progeny production
with the BRRF2 insertion mutant
To characterize the recombinant viruses, expression of lytic
viral proteins was ﬁrst determined using immunoblotting
(Fig. 3A). We chose two typical cell clones of each EBV-BAC
(wild-type, dBRRF2, and dBRRF2/R) for the analyses. Proteins were
prepared from the HEK293 cell clones containing the recombinant
EBV genome on 0 or 2 days after electroporation of the expression
vector for BZLF1. BRRF2 protein was absent in the knockout
whereas it was present in wild-type and revertant strains, as
expected (Fig. 3A). Importantly, we conﬁrmed that expression of
the neighboring gene products, BRRF1, BRLF1 (Rta), EBNA1
(BKRF1) was not reduced in the BRRF2-knockout virus (dBRRF2)
by marker cassette insertion (Fig. 3A). Although background
expression levels (day 0) of some of the proteins (e.g., BALF2,
BMRF1) were not necessarily consistent between cell clones, levels
of BZLF1, BRLF1 (IE), BALF2, BMRF1, BRRF1 (E), gB (L), and EBNA1
(latent) gene products were typically comparable on day 2
(Fig. 3A). Therefore, it was suggested that disruption of BRRF2
did not affect the production of viral proteins.
We next examined the levels of viral DNA synthesis in HEK293
cells expressing wild-type and recombinant viruses. qRT-PCR
analysis demonstrated that viral DNA levels of BRRF2-deﬁcient
viruses were comparable to those of wild-type or revertant viruses
(Fig. 3B), indicating that BRRF2 does not signiﬁcantly affect viral
DNA synthesis of the EBV genome. One of the revertant clones
showed lower DNA replication (Fig. 3B, rightmost bar) than the
other samples, but we assume this is within the range of
ﬂuctuations.
To determine viral yields, HEK293 cells carrying each EBV BAC
clone were transfected with the BZLF1 expression vector and
harvested together with culture medium 3 days after transfection,
followed by freezing and thawing. After centrifugation to clear cell
debris, the supernatants were co-cultured with EBV-negative
Akata cells (Akata(-)) and analyzed using FACS analysis. Since
recombinant EBV expresses GFP protein, Akata(-) cells infected
with EBV became GFP-positive. Levels of GFP-positivity, which was
indicative of progeny viral levels, were slightly but signiﬁcantly
decreased (about 25–50% those of wild-type or revertant viruses)
in the two representative knockout samples (Fig. 3C).
We then explored whether exogenous supply of BRRF2 in trans
could restore the reduced virus yield in the BRRF2-knockout virus.
Exogenous supply of BRRF2 in cells with wild-type EBV had almost
no effect on virus progeny production (Fig. 3D). In contrast, in the
BRRF2-knockout virus BRRF2 expression almost completely com-
plemented the titer (Fig. 3D). Protein levels were assessed
(Fig. 3E); results indicated that BRRF2 was absent in the knockout
virus, and the amount of BRRF2 produced in trans was similar to
that in the wild-type. This suggests that viral proteins, such as
BALF2, BMRF1, and gB, were expressed almost equally in the wild-
type and knockout with or without BRRF2.
To increase our understanding of progeny production, we
enumerated extracellular infectious particles (Fig. 4). HEK293 cells
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carrying each EBV BAC clone (wild-type, dBRRF2, and dBRRF2/R)
were transfected with the BZLF1 expression vector. Three days
after transfection, cells and media were collected separately by
low-speed centrifugation, followed by freezing and thawing. After
centrifugation to clear cell debris, the supernatants were co-
cultured with EBV-negative Akata cells (Akata(-)) and analyzed
by FACS. Interestingly, extracellular progeny virus levels of the
knockout virus were signiﬁcantly lower than those of the wild-
type or revertant strains, whereas intracellular or cell-associated
progeny levels were comparable (Fig. 4). Taken together, these
ﬁnding suggest that knockout of the BRRF2 gene decreased
production of progeny virus.
Phosphorylation of BRRF2 protein
Since it was reported that tegument BRRF2 protein in the virion
might be phosphorylated (Johannsen et al., 2004), we examined its
phosphorylation in infected cells (Fig. 5). To this end, we used a
Phostag gel. Since Phostag is a functional molecule that binds
speciﬁcally to the phosphate group, phosphoproteins are trapped
and their migration during electrophoresis reduced (Kinoshita-
Kikuta et al., 2007). HEK293 cells carrying the wild-type EBV BAC
clone were transfected with the BZLF1 expression vector, and 0 or
2 days after transfection, cell proteins were harvested, treated with
or without lambda phosphatase, and electrophoresed in a Phostag
gel or conventional SDS polyacrylamide gel (Fig. 5A). BRRF2
protein in infected cells migrated slowly in the Phostag gel (and
in a conventional gel, too, only slightly, though) when compared to
BRRF2 treated with lambda phosphatase (Fig. 5A). Differences in
band patterns between phosphatase-treated and untreated sam-
ples were somehow more marked when Flag-tagged BRRF2 was
used (Fig. 5B).
Because EBV encodes a protein kinase, BGLF4, we explored
whether BRRF2 protein could be phosphorylated by BGLF4-
knockout virus. Phostag electrophoresis showed that BRRF2 was
phosphorylated even in the absence of BGLF4 (Fig. 5C). BGLF4
protein was conﬁrmed to be absent in the knockout virus cells, as
expected (Fig. 5D). These results indicated that BRRF2 protein is
phosphorylated in lytically infected cells.
Fig. 1. Identiﬁcation of the BRRF2 protein. (A) BRRF2 protein produced in vitro was subjected to immunoblotting using an antibody against BRRF2. (B) B95-8 or HEK293 EBV-
BAC cells were treated with TPA (20 ng/ml), A23187 (1 μM), and sodium butyrate (5 mM) (T/A/B), or transfected with BZLF1 expression vector to induce the lytic cycle of EBV.
Cell proteins were subjected to immunoblotting using an antibody against BRRF2. (C) BRRF2 was expressed with late kinetics. B95-8 cells were incubated with (T/A/B) or
without (Cont) TPA (20 ng/ml), A23187 (1 μM), and sodium butyrate (5 mM). PAA (400 μg/ml) was also added (T/A/BþPAA) to inhibit viral DNA replication. After 2 days, cells
were harvested and subjected to immunoblotting using anti-BRRF2, –BALF2, –BMRF1, –BALF4 (gB), and-tubulin antibodies. (D) Subcellular localization of BRRF2 in HEK293
EBV-BAC cells. HEK293 cells expressing wild-type EBV were transfected with empty vector or the BZLF1 expression vector and incubated for 48 h. After ﬁxation,
immunoﬂuorescence assays were performed using anti-BRRF2 (red) and –BMRF1 (green) antibodies and analyzed using confocal microscopy. (E) Subcellular localization of
BRRF2 in B95-8 cells. B95-8 cells were transfected with BZLF1 and/or Flag-BRRF2 expression vector and incubated for 48 h. After ﬁxation, immunoﬂuorescence assays were
performed using anti-Flag (green) and –BMRF1 (red) antibodies and analyzed using confocal microscopy.
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Discussion
In this study, we identiﬁed the BRRF2 protein and examined the
physiological signiﬁcance of its gene by analyzing a knockout EBV. We
focused on this gene because the homolog of BRRF2 in MHV-68 was
reported to be essential for lytic replication (Song et al., 2005).
Unexpectedly, EBV BRRF2 was shown to be dispensable for lytic
replication, at least in HEK293 cells. Since we speculated that BRRF2
is essential for replication in B cells, we knocked down the BRRF2 gene
in B95-8 cells by transfection of siRNA (not shown). We used three
siRNAs of different target sequences in the BRRF2 ORF, all of which
effectively knocked-down the BRRF2 gene product. However, expres-
sion of viral proteins, viral DNA replication level, and yield of progeny
virus were not affected by knockdown of the BRRF2 gene. In fact,
unlike the result of knockout virus (Fig. 3), knockdown did not lead to a
reduction in progeny production. This may be because knockdown
efﬁciency was not complete and the remaining BRRF2 might have
mufﬂed the effect of BRRF2 knockdown. Actually, knockdown efﬁ-
ciency was fairly good and almost 100% of BRRF2 was ablated at least
on day 2, but the protein was present to some extent on day 3.
However, these knockdown data (not shown) and knockout virus data
(Fig. 3) strongly indicate that BRRF2 is not essential, in contrast to
reports regarding MHV-68 (Song et al., 2005). Since EBV and MHV-68
belong to the gamma1 and gamma2 herpesviruses, respectively, these
differences are not rare. For example, the BMRF1 gene of EBV is
essential for lytic replication (Nakayama et al., 2010; Neuhierl and
Delecluse, 2006), but its homolog ORF59 of MHV-68 is not required for
replication in ﬁbroblasts (Song et al., 2005). We recently found that the
EBV BGLF3.5 gene is not essential for lytic replication (Watanabe et al.,
2015), but its homolog in MHV-68, ORF35, is required (Song et al.,
2005), or at least plays a signiﬁcant role (Ohno et al., personal
communication), in viral lytic replication.
Although involvement of the BRRF2 gene product in virus produc-
tion is shown here (Fig. 3, 4), the underlying molecular mechanism
remains unclear. Since localization of BRRF2 was shown to be
cytoplasmic (Fig. 1D, E), it may contribute to maturation (e.g., tegu-
mentation, envelopment) or transportation of virus progeny. It is
obvious that extracellular virions were reduced by BRRF2 knockout
(Fig. 4), but we did not observe an accumulation of cell-associated
virions. Therefore, if there is an intracellular virion number threshhold
that needs to be surpassed for efﬁcient extracellular transportation, it
remains possible that the extracellular egress step is not blocked, but
yield may be too low in cells infected with the mutant virus. In any
event, it is difﬁcult to detect EBV capsid/virion, at least in HEK293 cells
because analysis of these EBV processes is hampered by the very low
levels of progeny capsids/virions in cells.
We observed phosphorylation of BRRF2 protein in infected cells,
which was independent of the only EBV protein kinase, BGLF4 (Fig. 5).
This was not surprising when intracellular localization of the two
proteins was taken into account; BRRF2 localizes in the cytoplasm
while BGLF4 is present predominantly in the nucleus. Although a few
cytoplasmic proteins are phosphorylated by BGLF4 (Kawaguchi et al.,
2003), BRRF2 is unaffected by the kinase in infected cells. We are now
attempting to identify the BRRF2 residue(s) that are phosphorylated.
When the phosphoresidue(s) are identiﬁed, we may be able to infer
the kinase responsible for BRRF2 phosphorylation according to the
sequence information around the phosphorylated residue(s). We can
also examine the physiological signiﬁcance of the BRRF2 phosphoryla-
tion using point mutagenesis. Immunoprecipitation followed by mass
spectrometry may also facilitate identiﬁcation of the phosphoresidue
(s). In addition, since the interaction of BRRF2 protein with other viral
or cellular proteins may be crucial, we are now attempting to identify
the interacting partners using immunoprecipitation/mass spectrometry
and other methods.
Intriguingly, anti-EBV BRRF2 antibody levels were higher in the
cerebrospinal ﬂuid and serum of multiple sclerosis patients than in
control donors (Cepok et al., 2005). It has been suggested that EBV
is involved in the pathognomonic immune response in multiple
sclerosis. It remains unclear why antibodies to only two EBV
proteins (BRRF2 and EBNA1) were identiﬁed, but it seems that
BRRF2 is also expressed in infected humans. It should be noted
that the BRRF2 is a lytic gene expressed with late kinetics (Fig. 1B,
C), although they argued that BRRF2 was expressed in latently
infected cells. Expression of BRRF2 protein in B95-8 cells without
lytic induction has been conﬁrmed, but we believe this to be due
to the low-level lytic replication of the virus in this cell line. We
also observed low-level expression of BRRF2 in uninduced B95-8
cells (Fig. 1B).
We report that the BRRF2 gene is not required for the EBV lytic
cycle, but reinforces virus production. Further studies are required
to clarify the molecular mechanisms underlying the increase in
viral egress. Research on BRRF2 protein phosphorylation may also
facilitate functional analysis of the gene product.
Materials and methods
Cell culture and reagents
HEK293 cells or its derivatives were maintained in Dulbecco's
modiﬁed Eagle medium (Gibco BRL) supplemented with 10% fetal
Fig. 2. Construction of insertion mutants of EBV BRRF2. (A) Schematic arrangement
of the recombination of the EBV genome using the selection marker cassette. The
tandemly arranged neomycin-resistance and streptomycin-sensitivity genes (Neo/
St) were inserted into nucleotide 660 to 661 of the BRRF2 gene to construct
dBRRF2. The Neo/St cassette was then replaced with a wild-type BRRF2 sequence to
construct the revertant virus dBRRF2/R. (B, C) Electrophoresis of the recombinant
viruses. EBV BAC DNAs were digested with BamHI (B) or EcoRI (C) and separated on
an agarose gel. The white arrowhead indicates the BamHI-R fragment of the virus.
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Fig. 3. Viral protein expression (A), DNA synthesis (B), and progeny production (C) in wild-type, BRRF2 deletion mutant and revertant viruses. (A) HEK293 cells, latently
infected with the indicated EBV genomes, were transfected with the BZLF1 expression vector and harvested on day 2. Immunoblotting was performed with anti-BZLF1, –
BALF2, –BMRF1, –BRLF1, –BRRF1, –BRRF2, –EBNA1, BALF4 (gB) and tubulin antibodies. (B) HEK293 cells with the indicated EBV genomes were transfected with BZLF1
expression vector and harvested on day 2. Viral DNA levels were determined using qRT-PCR. (C) HEK293 cells carrying the indicated EBV genomes were transfected with the
BZLF1 expression vector and harvested on day 3. After freezing/thawing and centrifugation, the supernatants were co-cultured with Akata(-) cells. GFP-positive cells were
counted using FACS. Statistical analysis was performed using Student's t test; * po0.002 compared to any row of wild-type or revertant (dBRRF2/R). (D, E) Complementation
of reduced titer in the mutant by exogenous supply of BRRF2. (D) HEK293 cells, latently infected with the indicated EBV genomes, were transfected with the BZLF1
expression vector plus empty vector (Z, gray bars) or BZLF1 plus BRRF2 (ZþR2, black bars) and harvested on day 3. After freezing/thawing and centrifugation, the
supernatants were co-cultured with Akata(-) cells. GFP-positive cells were counted using FACS. * indicates po0.002. (E) A part of the same sample in (D) was subjected to
immunoblotting with anti-BRRF2, –BZLF1, –BALF2, –BMRF1, –BALF4 (gB) and-tubulin antibodies.
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bovine serum. B95-8 and Akata(-) cells were cultured in RPMI1640
medium containing 10% fetal bovine serum. TPA, A23187 (calcium
ionophore), and PAA (DNA polymerase inhibitor) were purchased
from Sigma, and sodium butyrate (HDAC inhibitor) was purchased
from Wako Chemicals. Antiserum against BRRF2 was prepared by
immunizing with polypeptide RGGMGSLHLAKPEETSPC eight times
in a rabbit. The serumwas collected and afﬁnity-puriﬁed using the
same peptide. Antiserum against BRRF1 was prepared by immu-
nization with a GST-BRRF1 fusion protein, followed by afﬁnity
puriﬁcation. Antibodies against BZLF1, BMRF1, BALF2, BALF5,
BGLF4, and BALF4 were used as reported previously (Asai et al.,
2006; Daikoku et al., 2004; Murata et al., 2009a). Anti-tubulin
antibody was purchased from Cell Signaling. Mouse anti-Flag, anti-
BMRF1, and anti-Rta antibodies were purchased from Sigma,
Novocastra, and Argene Biosoft, respectively. Horseradish
peroxidase-linked goat antibodies to mouse or rabbit IgG were
purchased from Amersham Biosciences.
Plasmid construction
Two expression vectors, pcDNABZLF1 and pcDNAFlagBGLF4, have
been described previously (Murata et al., 2009a, 2009b). The expres-
sion vector for BRRF2 (pcDNABRRF2) was generated by cloning the
BRRF2 gene into pcDNA3. Primers used for BRRF2 ampliﬁcation were
50-ATCTGAATTCATGAGTGGGCAGCAGAGAGG-30 (forward) and 50-
TACTCGAGTTAGACGACGCTCAGTGAATAC-30 (reverse), where under-
lined sequences represent EcoRI and XhoI recognition motifs, respec-
tively. pcDNAFlagBRRF2 was constructed by inserting the BRRF2 ORF
into pcDNAFlag (Murata et al., 2009b). In vitro expression of BRRF2
protein was performed using the TnT Quick Coupled Reticulocyte
Transcription/Translation System (Promega).
Immunoﬂuorescence and confocal microscopy
Cells ﬁxed with 70% ethanol were seeded onto glass slides,
ﬁxed with 4% paraformaldehyde, and permeabilized with 0.1%
Triton-X100. Samples were then blocked using 10% normal goat
serum (Funakoshi) and stained with anti-BRRF2 rabbit antibody
and anti-BMRF1 mouse antibody, followed by washing, and then
with secondary antibody (Alexa 488 anti-mouse IgG and Alexa 546
anti-rabbit IgG, Invitrogen), followed by washing again, before
mounting with ProlongGold antifade reagent (Life Technologies)
(Sugimoto et al., 2013). Confocal microscopy (LSM510, Zeiss) was
used to analyze the samples.
B95-8 cells were transfected with pcDNABZLF1 and/or pcDNA-
FlagBRRF2. After PBS washing, cells were ﬁxed with 4% parafor-
maldehyde and permeabilized with 0.1% Triton-X100, followed by
blocking with 10% normal goat serum. Flag-tagged BRRF2 was
stained using an anti-Flag antibody and anti-mouse Alexa Fluor
463. Mouse anti-BMRF1 was directly labeled with Alexa Fluor 555
using Zenon Alexa IgG labeling reagent (Invitrogen).
Genetic manipulation of EBV-BAC DNA
EBV-BAC DNA was provided by W. Hammerschmidt (Delecluse
et al., 1998). Homologous recombination was performed in E. coli
as described previously (Isomura et al., 2008, 2004; Murata et al.,
2009a, 2013).
To obtain recombinant viruses, the kanamycin resistance gene
and the streptomycin sensitivity gene in the rpsL-neo (Gene
Bridges, Germany) were employed. DNA fragments for recombina-
tion were generated by PCR using rpsL-neo vector as a template
with the following primers: 50-CTCGATGACTCCGATGCTGTTTTCG-
CACGCACCTTATTGGCAGCCTTATTTCACCTCAATGGCCTGGTGAT-
GATGGCGGGATC-30 (forward) and 50-GAGGGCCTGCTTCAAGCTC-
ATGGAGTCTTGTGTTATGTAATCTTTGAGAATAAAGAACATCAGAA-
GAACTCGTCAAGAAGG-30 (reverse), where underlined nucleotides
denote sequences identical to the EBV BRRF2 gene. Recombination
was conﬁrmed by PCR using the following primers: 50-CGCC-
TGACTTTCACGAAATC-30 (forward) and 50-CGGAAAGCTTCCAAG-
TAGTC-30 (reverse). Revertant viruses were constructed using the
PCR fragment ampliﬁed using the above primers. Electroporation
was performed using Gene Pulser III (Bio-Rad), and puriﬁcation of
EBV-BAC DNA was achieved using NucleoBond Bac100 (Macherey-
Nagel, Germany).
Transfection, cell cloning and immunoblotting
EBV-BAC DNA was transfected into HEK293 cells using lipofec-
tamine 2000 reagent (Invitrogen). After transfection of Bac DNA,
cells were cultured in 10-cm dishes with 150 μg/ml of hygromycin
B for 10–15 days, and GFP-positive cell colonies were cloned as
described previously (Murata et al., 2009a). For each recombinant
virus, we picked hygromycin-resistant, GFP-positive cell colonies
and examined whether the cells exhibited minimal spontaneous
expression of viral lytic proteins and signiﬁcant induction of lytic
viral proteins upon BZLF1 transfection.
To induce lytic replication, HEK293 cells were transfected with
pcDNABZLF1 using the Neon Transfection System (Invitrogen). At
48 h after transfection, cells were washed with PBS and harvested
for immunoblotting (IB), as described previously (Murata et al.,
2009a).
For the Phostag gel electrophoresis, cells were lysed in 1x
Phosphatase bufferþNP40 (1x Lambda Phosphatase Buffer, 2 mM
MnCl2, 0.5% NP40, protease inhibitors) and treated with or with-
out Lambda Phosphatase (Santa Cruz). Lysates were then sepa-
rated on a SuperSep Phos-tag 7.5% gel (Wako Chemicals) and
subjected to immunoblotting. Since the transfer efﬁciency is poor,
Fig. 4. Extracellular virions were reduced by BRRF2 knockout. HEK293 cells
latently infected with the indicated EBV genomes were transfected with the BZLF1
expression vector and harvested on day 3. Cells were separated from media by low-
speed centrifugation. After freezing/thawing and centrifugation, the supernatants
were co-cultured with Akata(-) cells. GFP-positive cells were counted using FACS.
Three independent samples were assayed and Student's t test was performed.
n po0.002 compared to any row in the medium of the wild-type or revertant.
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zinc ions were removed from the gel by EDTA processing after
electrophoresis and before transfer to the membrane, according to
the manufacturer's instructions. SuperSep Phos-tag is a precast
polyacrylamide gel containing Phostag. Because Phostag is a small
molecule, speciﬁcally binds to the phosphate group, it retards the
migration of phosphoproteins (Kinoshita-Kikuta et al., 2007).
Quantiﬁcation of viral DNA synthesis during lytic replication
Levels of viral DNA were determined using qRT-PCR, as described
previously (Narita et al., 2013). Brieﬂy, cells in lysis buffer were
sonicated and treated with proteinase K. After deactivation of the
proteinase, qRT-PCR reactions were performed in a total volume of
10 μl containing 1 μM of each forward and reverse primer, 5 μl
FastStart Universal Probe Master (Rox) (Roche Applied Science),
eukaryotic 18S rRNA endogenous control (Applied Biosystems), and
1 μl of prepared DNA sample in PCR lysis buffer. The ROX dye intensity
was used to compensate for volume ﬂuctuations among the tubes. A
standard curve was constructed using serial dilutions of DNA and was
used to quantify the amount of DNA. Primers and a probe for detection
of the viral genome were designed against the BALF2-coding region.
The sequences were as follows: 50-GCCCGTCCGGTTGTCA-30 (forward
primer), 50-AATATCTGGTTGTTGCCGTTGA-30 (reverse primer), and 50-
FAM-CTGCCAGTGACCATCAACAAGTACACGG-TAMRA-30 (probe; where
FAM is 6-carboxyﬂuorescein and TAMRA is tetramethyl rhodamine).
FACS analysis
Akata(-) cells were infected with HEK293 culture supernatant.
After 48 h, Akata(-) cells were ﬁxed with 1% formaldehyde,
washed with PBS and suspended in PBS. GFP-positive cells were
counted using the FACS Calibur G5 system (Becton–Dickinson),
according to the manufacturer's instructions.
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